Introduction to Zoetis Inc.
Zoetis Inc. (NYSE: ZTS) stands as the premier global animal health company, dedicated to discovering, developing, manufacturing, and commercializing a broad portfolio of vaccines, medicines, diagnostics, and genetic tests for livestock and companion animals. Headquartered in Parsippany, New Jersey, Zoetis operates in over 45 countries and serves more than 100 markets worldwide. With an annual revenue exceeding $8 billion and a workforce of approximately 13,000 employees, Zoetis is recognized as a Fortune 500 company and a dominant force in the healthcare sector, specifically within the veterinary pharmaceutical and biologics industry. The company’s reputation is built on a foundation of scientific excellence, regulatory rigor, and a deep commitment to the health of animals—which, in turn, supports human health, food security, and economic prosperity. Organizations ranging from veterinary practices and animal hospitals to large-scale livestock producers and pet owners rely on Zoetis’ innovative solutions to prevent, treat, and manage disease.
Zoetis’ role in the industry is multifaceted. It not only produces blockbuster products like Apoquel (for canine atopic dermatitis) and Simparica Trio (parasiticide) but also invests heavily in research and development to pioneer gene-editing technologies, monoclonal antibodies, and precision livestock farming tools. The company’s scale allows it to influence global health standards, collaborate with governments on zoonotic disease surveillance, and drive sustainability in food animal production. As a member of the S&P 500 and the Dow Jones Sustainability Index, Zoetis consistently earns top marks for ethical practices, innovation, and corporate responsibility. For professionals in healthcare and life sciences, Zoetis represents an employer of choice where science meets meaningful impact.
Company History and Business Evolution
Zoetis Inc. was born out of Pfizer’s animal health division, which had been operational for over six decades before its separation. On February 6, 2013, Pfizer spun off the division into an independent publicly traded company, marking the largest veterinary initial public offering in history—raising nearly $2.6 billion. The name “Zoetis” derives from the Greek word “zoē” (life), reflecting its mission to improve animal well-being. The newly formed company inherited a rich portfolio of legacy products, a robust R&D pipeline, and a global network of manufacturing sites. However, management quickly set out to establish its own identity, investing in digital health, biologics manufacturing expansion, and strategic acquisitions.
Key milestones in Zoetis’ evolution include the 2014 acquisition of Pharmacia & Upjohn’s animal health business, which added key vaccines and reproductive solutions. In 2015, Zoetis purchased Abbott’s animal health diagnostics business, strengthening its point-of-care testing capabilities. The 2017 acquisition of Nexvet, a leader in monoclonal antibodies for pets, launched Zoetis into the high-growth specialty therapeutics segment. More recently, the 2021 purchase of Jurox, an Australian animal health company, expanded its parasiticides and pain management line. Zoetis also entered the rapidly growing canine cancer market through its acquisition of VetDC in 2021 and has made strategic investments in genomics (e.g., the 2019 launch of the Clarify™ cat allergy test and the Igenity® platform for livestock). Beyond acquisitions, Zoetis pioneered the use of wearable sensors and telemedicine platforms, such as the VetSight® wearable and the Zoetis Pet Care app. The company’s innovation pipeline today includes over 300 active projects, covering everything from avian influenza vaccines to anti-obesity therapeutics for pets.
Zoetis Inc. at a Glance
Here are 20 searchable facts that define Zoetis Inc.:
- Headquarters: Parsippany, New Jersey, USA.
- Founded: 2012 (spun off from Pfizer; began operations as a standalone company in 2013).
- CEO: Kristin Peck (since 2020).
- Revenue: $8.5 billion (2023 fiscal year).
- Employees: Approximately 13,000 globally.
- Stock Symbol: ZTS (NYSE).
- Industry: Animal Health (Veterinary Pharmaceuticals, Biologics, Diagnostics, Genetics).
- Market Cap: Over $90 billion (as of 2024).
- Global Presence: Operations in 45+ countries, products sold in 100+ markets.
- R&D Investment: Approximately $500 million annually.
- Flagship Products: Apoquel (canine atopic dermatitis), Simparica Trio (parasiticide), Revolution (topical parasiticide), Cytopoint (injectable for canine allergies), Vanguard (vaccines), Excede (antibiotic for cattle).
- Acquisitions: Nexvet (2017), Jurox (2021), VetDC (2021), Abbott's animal health diagnostics (2015).
- Manufacturing Sites: 28 manufacturing facilities across 12 countries.
- Key Competitors: Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health, IDEXX Laboratories.
- Corporate Social Responsibility: Zoetis Health for Animals program, global disease surveillance, sustainability goals (Net Zero by 2040).
- Digital Health: Zoetis Pet Care App, VetSight Wearable, telemedicine platforms.
- Genomics: Igenity® (livestock genomic profiling), Clarify™ (feline allergy test).
- Employee Recognition: Named one of Fortune’s “World’s Most Admired Companies” (2023).
- Global Collaboration: Partnerships with World Organisation for Animal Health (WOAH), International Federation for Animal Health (IFAH).
- CEO Tenure: Kristin Peck, only the second CEO in company history, previously served as Executive Vice President of Zoetis’ U.S. Operations.
Mission, Vision, and Core Corporate Values
Zoetis operates with a clear mission: “To nurture the world and humankind by advancing care for animals.” This mission underscores the intimate link between animal health and human well-being—healthy animals mean safe food, reduced zoonotic disease risks, and the emotional benefits of pet companionship. The vision complements this: “To be the world’s most trusted partner in animal health.” Trust is earned through scientific rigor, regulatory compliance, transparency, and consistent outcomes. The company’s core values are embedded in its daily operations: Courage (to challenge the status quo and innovate), Ownership (taking accountability for results and safety), Collaboration (working across boundaries to deliver solutions), and Integrity (operating ethically and sustainably). These values are not mere posters; they are assessed in performance reviews, reflected in executive decisions, and celebrated in employee recognition programs. Zoetis also prioritizes diversity, equity, and inclusion (DE&I) as a strategic imperative, with employee resource groups for women, people of color, LGBTQ+, and veterans. The company regularly publishes an annual Global Sustainability Report detailing progress on environmental, social, and governance (ESG) metrics, including carbon footprint reduction, water conservation, and community health initiatives.
Business Strategy and Future Roadmap
Zoetis’ strategy rests on three pillars: Innovate, Bring, and Commercialize. The company continuously invests in internal R&D and external partnerships to create novel therapies for high-need areas (e.g., oncology, parasitology, pain management). Its pipeline includes next-generation vaccines using recombinant DNA technology, monoclonal antibodies for chronic conditions, and gene therapies for inherited disorders. The second pillar, “Bring,” focuses on rapid market access—streamlining regulatory approvals across key regions (U.S., EU, China, Brazil) and leveraging digital tools to accelerate time-to-market. The third pillar, “Commercialize,” involves building strong brand awareness among veterinarians, distributors, and pet owners, while using data analytics to tailor marketing campaigns.
Looking ahead, Zoetis sees growth opportunities in three areas: (1) Precision Livestock Farming—using sensor data, genomics, and AI to optimize animal health and productivity; (2) Pet Specialty Care—expanding into niche markets like veterinary oncology, dermatology, and immunology; and (3) Emerging Markets—penetrating countries with rising pet ownership and livestock intensification, such as China, India, and Brazil. The company also aims to achieve carbon neutrality by 2040 and reduce water usage by 30% by 2030. In the next five years, Zoetis expects to file over 30 new product registrations and launch at least five major biosimilars for livestock. Its digital health platform, Zoetis Dx, will integrate diagnostic data from point-of-care devices with electronic health records, enabling predictive analytics for disease outbreaks. The company’s commitment to innovation is reflected in its $500 million annual R&D budget and its 300+ ongoing clinical trials.
Products, Technologies, and Services
Zoetis offers a comprehensive portfolio of products across four major categories: Pharmaceuticals (including anti-infectives, parasiticides, anti-inflammatory drugs, and pain management), Vaccines (for both livestock and companion animals), Diagnostics (rapid tests for infectious diseases, allergy testing, and genetic screening), and Genetics (genomic profiling for cattle, swine, and poultry). Key products include Apoquel (the world’s 1 dermatology product for dogs), Simparica Trio (a triple-combination parasiticide for dogs), Revolution Plus (for cats), and Vanguard vaccines for dogs and cats. In the livestock segment, Zoetis offers Excede (antibiotic for cattle), Draxxin (antimicrobial for swine and cattle), and Improvest (immunological product for boar taint control). Technologies like the VetSight wearable device continuously monitor a pet’s vital signs and transmit data to the veterinarian. The Zoetis Pet Care App allows owners to track vaccination schedules, order prescription refills, and consult vets via telehealth. For diagnostics, the VETSCAN line provides in-clinic chemistry analyzers, while the Witness® line offers rapid lateral flow tests for heartworm, parvovirus, and feline leukemia.
The company’s services extend beyond product sales. Zoetis offers practice management software (e.g., Blyss for veterinary clinics), continuing education programs for veterinarians (Zoetis VetEd), and market analytics tools (Zoetis Insight). Its Igenity® genomics service helps cattle producers select for traits like feed efficiency, marbling, and disease resistance. Additionally, Zoetis operates a specialized pharmacovigilance platform to monitor adverse events globally. Through its Animal Health Innovation Program (AHIP), the company funds early-stage research at universities and startups. All products and services are backed by a global quality assurance system that meets the stringent standards of the FDA, EMA, and other regulatory authorities.
Industries and Markets Served
Zoetis serves a diverse set of industries: Veterinary Medicine (companion animal clinics, veterinary referral hospitals, shelter medicine), Livestock Production (cattle, swine, poultry, aquaculture, and sheep), Food Safety (antibiotic stewardship and residue testing), Public Health (zoonotic disease surveillance), and Research & Academia (diagnostic tools and animal models). Within these sectors, the key customer segments include veterinarians (who prescribe and administer products), distributors (such as MWI Animal Health and Covetrus), large-scale animal producers (e.g., Tyson Foods, Cargill), and retail pet supply chains (PetSmart, Chewy). Zoetis also works with government agencies like the USDA and WHO to tackle diseases like rabies, avian influenza, and African swine fever. The company divides its business into two segments: Companion Animal (~55% of revenue) and Livestock (~45%). Geographically, North America contributes about 55% of sales, followed by Europe/Africa (20%), Latin America (15%), and Asia Pacific (10%).
Leadership and Management Philosophy
Zoetis’ leadership team is led by CEO Kristin Peck, who took the helm in 2020. Peck previously served as EVP of U.S. Operations and brings a strong commercial and operational background. The executive committee includes leaders from diverse fields: R&D, manufacturing, regulatory, digital health, and sustainability. Zoetis promotes a flat organizational structure where regional presidents have significant autonomy. The management philosophy centers on “Performance with Purpose”—a focus on delivering financial results while making a positive impact on animals, people, and the planet. Leaders are expected to exhibit “Zoetis Leadership Attributes”: Strategic Agility, Results Orientation, Team Development, and Ethical Courage. The company uses a 360-degree feedback system and encourages open dialogue through quarterly town halls and an anonymous “Speak Up” hotline. Management also champions employee well-being through flexible work arrangements, mental health support, and career development programs.
Corporate Events, Conferences, and Community Engagement
Zoetis is a prominent sponsor and participant in major veterinary conferences, including the American Veterinary Medical Association (AVMA) Convention, the North American Veterinary Community (NAVC) Conference, the World Veterinary Association Congress, and the Animal Health Summit. The company also hosts its own events: the Zoetis Veterinary Leadership Forum (held annually in Orlando), the Zoetis Innovation Summit (featuring startup pitches and technology showcases), and regional “Zoetis Academy” training sessions for veterinarians. In the community, Zoetis engages through the Zoetis Foundation, which has donated millions to animal welfare organizations, veterinary schools, and disaster relief efforts (e.g., Hurricanes Harvey and Maria). The “Zoetis Gives Back” program encourages employees to volunteer, offering 8 hours of paid leave annually for community service. In 2023, Zoetis committed $15 million to a four-year initiative improving access to veterinary care in underserved communities.
Employees and Workplace Culture
Zoetis employs approximately 13,000 people worldwide, with a diverse workforce spanning scientists, veterinarians, sales representatives, supply chain experts, and data analysts. The company culture is described as “scientific, collaborative, and entrepreneurial.” Employees enjoy competitive compensation, including stock options, performance bonuses, and tuition reimbursement. Zoetis has been recognized as a “Top Employer” by the Science Careers survey for consecutive years and has achieved top scores on the Human Rights Campaign’s Corporate Equality Index. The workplace emphasizes continuous learning through Zoetis University (online courses) and a mentorship program. Flexible work arrangements are available for many roles, and the Parsippany headquarters features a state-of-the-art innovation lab, a fitness center, and a pet-friendly policy (employees can bring their dogs to work). Employee networks include Women in Zoetis, Zoetis Pride, and Zoetis Veterans.
Job Details & Requirements for this Posting
Position: Senior Director of Global Regulatory Affairs, Animal Health
Location: Parsippany, New Jersey (Hybrid work model – 3 days on-site per week).
Job Type: Full-time
Salary Range: $240,000 – $300,000 per year, plus equity and comprehensive benefits.
Role Summary: The Senior Director of Global Regulatory Affairs will lead a team of regulatory professionals responsible for the strategy and execution of worldwide product registrations for Zoeties’ companion animal and livestock portfolio. This executive will interface with health authorities (FDA/CVM, EMA, USDA, other national agencies) to ensure timely approvals while managing post-market compliance and lifecycle management. The ideal candidate will combine deep regulatory expertise with strategic thinking, as this role directly influences the company’s future product pipeline and market access.
Key Responsibilities:
- Develop and implement global regulatory strategies for new chemical entities, biologics, and combination products.
- Lead preparation and submission of marketing authorization applications (MAAs), investigational new animal drug applications (INADs/NADAs), and supplemental filings.
- Serve as the primary point of contact for regulatory agencies during reviews, inspections, and negotiations.
- Monitor and interpret changes in international regulatory requirements (e.g., VICH guidelines, ICH for veterinary products) and adapt strategies accordingly.
- Partner with R&D, Quality, and Commercial teams to align regulatory deliverables with business priorities.
- Manage a team of 5-10 direct reports, providing mentorship and professional development opportunities.
- Oversee the compilation of safety and efficacy data packages, including environmental impact assessments.
- Represent Zoetis in industry trade associations (IFAH, Animal Health Institute) to shape policy.
Qualifications:
- Advanced degree (Ph.D., DVM, or Pharm.D.) in life sciences, veterinary medicine, or related field.
- Minimum 15 years of experience in regulatory affairs within the pharmaceutical or animal health industry.
- At least 8 years in a leadership role with proven ability to manage complex global projects.
- In-depth knowledge of U.S. FDA/CVM, EMA, and at least one major emerging market (e.g., China, Brazil) regulatory frameworks.
- Track record of successful submissions leading to approvals for at least 3 major products.
- Excellent written and verbal communication skills; ability to distill complex science into clear regulatory arguments.
- Experience with biologics (vaccines, monoclonal antibodies) is highly preferred.
- Certifications such as RAC (Regulatory Affairs Certification) are a plus.
Why Candidates Should Join Zoetis Inc.:
Joining Zoetis means becoming part of a company that truly makes a difference—in the lives of animals, the health of people, and the sustainability of our planet. As a Senior Director, you will have global impact, shaping the regulatory landscape for breakthrough veterinary therapies. Zoetis offers a competitive compensation package, including performance bonuses, equity grants, 401(k) with match, generous paid time off, and subsidized child/elder care. Employees also gain access to cutting-edge scientific resources, cross-functional mentorship, and the ability to collaborate with world-class researchers. Zoetis is consistently ranked among the best employers, and its culture of innovation, diversity, and integrity ensures that your career will grow alongside the company’s ambitious goals.
Customer Reviews and Industry Reputation
Zoetis maintains a strong reputation across various review platforms. Below is an exhaustive analysis of feedback from employees, partners, and customers.
Glassdoor
On Glassdoor, Zoetis holds a 4.2 out of 5-star rating based on over 2,800 reviews. Employees praise the high level of autonomy, innovative culture, and strong focus on animal health. Many sales representatives and R&D scientists highlight the competitive compensation and positive work environment. Areas of critique include occasional silos between departments and a desire for more development opportunities in niche technical roles. However, 86% of employees would recommend Zoetis to a friend, and 89% approve of the CEO, Kristin Peck. The company’s ratings for culture and values (4.1) and career opportunities (3.9) are above industry average.
Indeed
Indeed reviews average 4.0 out of 5. Employees frequently note the meaningful nature of the work—“You get to help animals and their owners every day,” one reviewer wrote. The work-life balance is generally rated as good, especially in corporate roles. Some warehouse and manufacturing associates express concerns about shift schedules and physical demands. Zoetis’ response rate to negative reviews is high, indicating management’s attentiveness.
Gartner Peer Insights
Gartner reviews from IT professionals and digital health leaders highlight Zoetis’ robust investment in technology. The Zoetis Dx diagnostic platform receives an average rating of 4.5 out of 5 for ease of use and integration with veterinary practice software. Some users request more customization options, but overall satisfaction is strong.
Trustpilot
On Trustpilot, Zoetis’ customer-facing products (e.g., pet medications purchased through the Zoetis Pet Care app) have mixed reviews—average 3.8 stars. Pet owners appreciate the convenience but occasionally report shipping delays or difficulty reaching customer support. Zoetis actively replies to negative feedback, offering refunds or replacements, which helps maintain brand trust.
G2
Zoetis is not a typical software company, but its practice management software (Blyss) is reviewed on G2 with a rating of 4.2 stars. Veterinarians value the scheduling tools and client communication features, while some have suggested improvements in inventory management integration.
Google Reviews
The Zoetis corporate headquarters in Parsippany has a Google Maps rating of 4.5 stars (100+ reviews). Employees and visitors mention the modern campus, welcoming atmosphere, and pet-friendly policy. A few reviews mention traffic congestion in the area.
LinkedIn Reputation
Zoetis has over 300,000 followers on LinkedIn and is recognized as a “Top Company” in the Healthcare & Biotechnology category. The company posts regular thought leadership articles, product launches, and DE&I initiatives. Employee profiles often showcase career growth and volunteer activities. The company’s LinkedIn “Life” page features video testimonials and a robust Careers section.
Why Organizations Choose Zoetis Inc.
Veterinary practices, livestock producers, and distributors select Zoetis for its unparalleled product portfolio, scientific credibility, and customer support. The company’s extensive R&D pipeline ensures a steady stream of innovative therapies, while its global regulatory expertise minimizes market entry delays. Zoetis also offers flexible financing options for small clinics and comprehensive training programs. For large agribusinesses, Zoetis’ genomics and digital tools help optimize herd health and productivity. The company’s commitment to antibiotic stewardship (e.g., the “Zoetis Pledge” to reduce unnecessary antibiotic use) aligns with consumer demand for sustainable food.
Official Contact Information
For inquiries and assistance, please reach out to Zoetis Inc. using the following contact details:
Address: 100 Campus Drive, Florham Park, NJ 07932, USA
Contact Number: +1-888-963-8471 (Toll-Free)
Support Number: +1-973-822-7000
Helpdesk Number: +1-844-496-8472 (Veterinary Support)
Website: Zoetis Official Website
Official Social Media Presence
Follow Zoetis on LinkedIn: Zoetis LinkedIn | Twitter: @Zoetis | Facebook: Zoetis Facebook | Instagram: Zoetis Instagram | YouTube: Zoetis YouTube
SEO FAQ Section
1. What products does Zoetis Inc. manufacture for companion animals?Zoetis Inc. produces a wide array of products for companion animals, including Apoquel for allergies, Simparica Trio for parasites, Revolution for heartworm and fleas, Cytopoint for dermatitis, and Vanguard vaccines.
2. Where is Zoetis Inc. headquartered?Zoetis Inc. is headquartered in Parsippany, New Jersey, with additional major offices in Florham Park, New Jersey.
3. How many employees work at Zoetis Inc.?Zoetis Inc. employs approximately 13,000 people globally across its manufacturing, R&D, sales, and administrative functions.
4. Who is the CEO of Zoetis Inc.?The CEO of Zoetis Inc. is Kristin Peck, who has led the company since January 2020.
5. What is the mission of Zoetis Inc.?The mission of Zoetis Inc. is to nurture the world and humankind by advancing care for animals, linking animal health to human well-being.
6. Does Zoetis Inc. offer vaccines for livestock?Yes, Zoetis Inc. offers a full range of vaccines for livestock, including those for bovine respiratory disease, porcine circovirus, and avian influenza.
7. When was Zoetis Inc. founded?Zoetis Inc. was founded in 2012 as a spin-off from Pfizer and began independent operations in February 2013.
8. What is the stock symbol for Zoetis Inc.?Zoetis Inc. trades on the New York Stock Exchange under the ticker symbol ZTS.
9. Is Zoetis Inc. a sustainable company?Yes, Zoetis Inc. is committed to sustainability, aiming for carbon neutrality by 2040 and reducing water usage by 30% by 2030, as detailed in its annual Global Sustainability Report.
10. How can I purchase Zoetis Inc. products for my pet?Zoetis Inc. products for pets are available through licensed veterinarians or via the Zoetis Pet Care app, which connects pet owners to veterinary professionals.
11. What is the revenue of Zoetis Inc.?Zoetis Inc. reported revenue of approximately $8.5 billion in the 2023 fiscal year.
12. Does Zoetis Inc. have a mobile app for pet owners?Yes, Zoetis Inc. offers the Zoetis Pet Care App, which allows owners to manage health records, order medications, and consult with veterinarians via telemedicine.
13. Who are the main competitors of Zoetis Inc.?Main competitors of Zoetis Inc. include Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health, and IDEXX Laboratories.
14. What research areas does Zoetis Inc. focus on?Zoetis Inc. focuses on research in parasitology, dermatology, oncology, pain management, immunology, and precision livestock farming using genomics and data analytics.
15. Does Zoetis Inc. provide continuing education for veterinarians?Yes, Zoetis Inc. offers the Zoetis VetEd program, which includes online courses, webinars, and live seminars for veterinary professionals.
16. How can I apply for jobs at Zoetis Inc.?Interested candidates can apply for positions at Zoetis Inc. through the careers page on its official website, zoetis.com/careers.
17. What is the company culture like at Zoetis Inc.?Zoetis Inc. culture is described as scientific, collaborative, and innovative, with a strong emphasis on work-life balance, diversity, and pet-friendly workplaces.
18. Does Zoetis Inc. make vaccines for humans?No, Zoetis Inc. exclusively produces animal health products, not human vaccines or medicines.
19. What diagnostic tests does Zoetis Inc. offer?Zoetis Inc. offers a range of diagnostic tests, including VETSCAN analyzers for blood chemistry, Witness rapid lateral flow tests, and the Clarify test for feline allergies.
20. How can I contact Zoetis Inc. for investor relations?Investor relations for Zoetis Inc. can be reached via email at investorrelations@zoetis.com or through the investor section of zoetis.com.
Branded External References
For organizations seeking to build a robust online presence and generate high-quality backlinks, professional SEO Guest Posting Services provide a strategic advantage. Zoetis Inc. leverages similar content marketing principles to educate veterinarians and animal owners about its products. The company’s official website, Zoetis Inc., serves as the authoritative hub for all corporate information, product data, and career opportunities. By combining a strong digital strategy with scientific expertise, Zoetis maintains its leadership in the animal health industry while helping partners improve their search engine rankings through relevant, high-authority guest posts.
", "location": "Parsippany, New Jersey, United States (Hybrid)", "salary": "$240,000 - $300,000 per year", "job_type": "Full-time" }